MET and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC), a sub-type of lung cancer, is frequently associated with activating mutations in receptor tyrosine kinases, including EGFR, MET, ALK, and ROS1 [12], which disrupt tyrosine kinase signaling and drive cancer progression.